Source: International Congress 2018 – Basic pharmacology
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Yarova (Cardiff, United Kingdom), M. Schepelmann (Cardiff, United Kingdom), S. Ferla (Cardiff, United Kingdom), P. Huang (Cardiff, United Kingdom), V. Telezhkin (Newcastle upon Tyne, United Kingdom), E. Kidd (Cardiff, United Kingdom), W. Ford (Cardiff, United Kingdom), K. Broadley (Cardiff, United Kingdom), J. Ward (London, United Kingdom), C. Corrigan (London, United Kingdom), P. Kemp (Cardiff, United Kingdom), A. Brancale (Cardiff, United Kingdom), D. Riccardi (Cardiff, United Kingdom). Development of a new calcilytic for the treatment of inflammatory lung disease. 1060

Member's Comments

No comment yet.

Related content which might interest you: Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Modeling human pulmonary inflammatory diseases and therapeutic responses in a microfluidic lung airway-on-a-chip Source: International Congress 2015 – New models for treating airway diseases Year: 2015 Severe fibrotic lung disease – How much therapy is too much therapy? Source: Annual Congress 2008 - Clinical Grand Round - an interactive session Year: 2008 Optimising disease models for lung diseases and drug development Source: International Congress 2015 – Development and application of new approaches for respiratory disease research Year: 2015 Role of IL23 in the development of fibrotic interstitial lung disease Source: International Congress 2019 – New mechanistic insights into pulmonary fibrosis Year: 2019 Local and systemic neutrophilic inflammation in patients with lung cancer and chronic obstructive pulmonary disease Source: Annual Congress 2013 –Pathogenesis and risk of lung cancer Year: 2013 Azithromycin in the treatment of children with chronic inflammatory lung disease (CILD) Source: Eur Respir J 2004; 24: Suppl. 48, 391s Year: 2004 Nintedanib reduces fibrotic markers in the lung in a model of rheumatoid arthritis associated interstitial lung disease Source: International Congress 2016 – ILD pathogenesis Year: 2016 Human small airway-on-a-chip: A novel microphysiological system to model lung inflammation, accelerate drug development and enable inhalational toxico-analysis Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 Antifibrotic treatment in progressive non-IPF fibrotic interstitial lung diseases Source: International Congress 2019 – The world of idiopathic pulmonary fibrosis Year: 2019 Practical treatment of CF lung disease Source: ERS course 2015 Year: 2015 Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival Source: International Congress 2019 – Comorbidities of idiopathic pulmonary fibrosis Year: 2019 Biomarker discovery, development, and implementation in interstitial lung diseases Source: Virtual Congress 2021 – Interstitial lung diseases: from disease mechanisms to novel treatment options Year: 2021 COPD as a lung disease with heterogeneous systemic inflammatory consequences: clinical impact Source: Research Seminar 2011 - Physical activity, nutritional status and systemic inflammation in COPD Year: 2011 Interference RNA as a new tool and possible future therapy for inflammatory lung disease Source: Lung Science Conference 2005 - Evidence-based medicine for respiratory disease with special emphasis on inflammatory processes Year: 2005 Emerging anti-inflammatory strategies for COPD}, Source: Eur Respir J 2012; 40: 724-741 Year: 2012 Strong reversal of the lung fibrosis disease signature by autotaxin inhibitor GLPG1690 in a mouse model for IPF Source: International Congress 2016 – Therapeutic horizons: novel targets and pharmacological models Year: 2016 How systemic inflammatory diseases affect the lung Source: Virtual Congress 2020 – Interstitial lung diseases Year: 2020